Cost-utility analysis of surgical revascularization versus conservative management for adult moyamoya disease patients with posterior hemorrhage in Japan
AIMS: This study evaluates the cost-effectiveness of surgical revascularization versus conservative management for adult moyamoya disease (MMD) patients with posterior hemorrhage from the perspective of the Japanese public healthcare payer. MATERIALS AND METHODS: We developed a combined decision tree and Markov model for adult posterior hemorrhagic MMD patients (mean age: 41 years; baseline modified Rankin Scale [mRS] 0-2) over a 60-year lifetime horizon with 1-year cycles. We estimated the treatment effect using the composite endpoint hazard ratio (0.07) from the JAM Trial posterior hemorrhage subgroup as a proxy for the effect on recurrent hemorrhage. We informed health utilities with recent EQ-5D-5L data from the Fukuoka Stroke Registry, weighted by the Japan Stroke Data Bank. We estimated direct medical costs based on the national fee schedule. We discounted costs and outcomes at 2% annually. We set the willingness-to-pay threshold at JPY 7,500,000 per quality-adjusted life year (QALY). RESULTS: In the base case, surgical revascularization yielded 21.49 QALYs for JPY 6,323,426 (USD 40,302), compared with 15.59 QALYs and JPY 5,308,637 (USD 33,835) for conservative management. The incremental cost-effectiveness ratio was JPY 172,220 (USD 1,098) per QALY, which falls below the reference value of JPY 7,500,000 per QALY. In scenario analyses with 5- and 10-year horizons, the ICERs were JPY 8,926,784 and JPY 2,031,693 per QALY, respectively. Probabilistic sensitivity analysis also favored surgical revascularization across the modeled parameter distributions. LIMITATIONS: The base-case estimate of surgical efficacy was based on a composite outcome from a small subgroup, and long-term recurrence risks beyond the 5-year trial period remain uncertain. CONCLUSION: Surgical revascularization is likely to be cost-effective for adult MMD patients with posterior hemorrhage within the Japanese healthcare system, although limited evidence leaves uncertainty about long-term rebleeding risks and the durability of surgical benefit.
Authors
- Honoka Tamori (ORCID: https://orcid.org/0000-0002-2196-2538)
- Toshiya Osanai (ORCID: https://orcid.org/0000-0001-5570-1726)
- Katsuhiko Ogasawara (ORCID: https://orcid.org/0000-0001-5474-7861)
- Haruto Uchino (ORCID: https://orcid.org/0000-0001-6567-8136)
- Yasuhiro Morii (ORCID: https://orcid.org/0000-0003-1392-3229)
- Sachie Inoue (ORCID: https://orcid.org/0000-0002-1198-731X)
- Miki Fujimura
Institutions
- Hokkaido University (JP)
- Muroran Institute of Technology (JP)
- National Institute of Public Health (JP)
- National Institute of Public Health (SI)
- National Institute of Public Health (LA)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1080/13696998.2026.2756197
- Primary Topic
- Moyamoya disease diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hokkaido University